Cardiovascular complications of COVID-19

The objective: based on publications to provide up-to-date information on the frequency, basic variants and predictive significance of cardiovascular complications of the coronavirus infection caused by SARS-CoV-2.Results: the article identifies variants of cardiovascular disorders in COVID-19 cause...

Full description

Saved in:
Bibliographic Details
Main Authors: I. A. Kozlov, I. N. Tyurin
Format: Article
Language:Russian
Published: New Terra Publishing House 2020-09-01
Series:Вестник анестезиологии и реаниматологии
Subjects:
Online Access:https://www.vair-journal.com/jour/article/view/446
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849344022745710592
author I. A. Kozlov
I. N. Tyurin
author_facet I. A. Kozlov
I. N. Tyurin
author_sort I. A. Kozlov
collection DOAJ
description The objective: based on publications to provide up-to-date information on the frequency, basic variants and predictive significance of cardiovascular complications of the coronavirus infection caused by SARS-CoV-2.Results: the article identifies variants of cardiovascular disorders in COVID-19 caused by various comorbidities in particular hypertension, specific virus-associated myocardial damage, and side effects of medications. It analyzes the role of angiotensin-converting enzyme 2 type II receptors during infection with the coronavirus and potential changes in the renin–angiotensin–aldosterone system including in patients receiving angiotensin-converting enzyme inhibitors or blockers of angiotensin receptors. The data on the frequency and prognostic role of arrhythmias, virus-associated myocardial damage and heart failure, the risk of ischemia, and myocardial infarction are presented. The adverse cardiovascular events of drugs of different groups prescribed for treatment of COVID-19 and possible drug interactions are described. The current recommendations for cardiotonic and cardioprotective therapy in patients with cardiovascular complications are analyzed.Conclusion. The SARS-Cov-2 virus has a pronounced cardiac tropic effect which requires maximum cardiac alertness in the treatment of patients in this category, timely use of electrocardiography, echocardiography, control of biomarkers of myocardial damage and tension, as well as a reasonable use of cardiotonic and cardioprotective drugs.
format Article
id doaj-art-c9b80f1961f04deebf614d2d64bfbce1
institution Kabale University
issn 2078-5658
2541-8653
language Russian
publishDate 2020-09-01
publisher New Terra Publishing House
record_format Article
series Вестник анестезиологии и реаниматологии
spelling doaj-art-c9b80f1961f04deebf614d2d64bfbce12025-08-20T03:42:47ZrusNew Terra Publishing HouseВестник анестезиологии и реаниматологии2078-56582541-86532020-09-01174142210.21292/2078-5658-2020-17-4-14-22388Cardiovascular complications of COVID-19I. A. Kozlov0I. N. Tyurin1M.F. Vladimirsky Moscow Regional Research Clinical InstituteCity Clinical Hospital no. 40, Moscow Health Department; Pirogov Russian National Research Medical UniversityThe objective: based on publications to provide up-to-date information on the frequency, basic variants and predictive significance of cardiovascular complications of the coronavirus infection caused by SARS-CoV-2.Results: the article identifies variants of cardiovascular disorders in COVID-19 caused by various comorbidities in particular hypertension, specific virus-associated myocardial damage, and side effects of medications. It analyzes the role of angiotensin-converting enzyme 2 type II receptors during infection with the coronavirus and potential changes in the renin–angiotensin–aldosterone system including in patients receiving angiotensin-converting enzyme inhibitors or blockers of angiotensin receptors. The data on the frequency and prognostic role of arrhythmias, virus-associated myocardial damage and heart failure, the risk of ischemia, and myocardial infarction are presented. The adverse cardiovascular events of drugs of different groups prescribed for treatment of COVID-19 and possible drug interactions are described. The current recommendations for cardiotonic and cardioprotective therapy in patients with cardiovascular complications are analyzed.Conclusion. The SARS-Cov-2 virus has a pronounced cardiac tropic effect which requires maximum cardiac alertness in the treatment of patients in this category, timely use of electrocardiography, echocardiography, control of biomarkers of myocardial damage and tension, as well as a reasonable use of cardiotonic and cardioprotective drugs.https://www.vair-journal.com/jour/article/view/446covid-19sars-cov-2myocardial damageviral myocarditiscardiovascular complicationsarrhythmias
spellingShingle I. A. Kozlov
I. N. Tyurin
Cardiovascular complications of COVID-19
Вестник анестезиологии и реаниматологии
covid-19
sars-cov-2
myocardial damage
viral myocarditis
cardiovascular complications
arrhythmias
title Cardiovascular complications of COVID-19
title_full Cardiovascular complications of COVID-19
title_fullStr Cardiovascular complications of COVID-19
title_full_unstemmed Cardiovascular complications of COVID-19
title_short Cardiovascular complications of COVID-19
title_sort cardiovascular complications of covid 19
topic covid-19
sars-cov-2
myocardial damage
viral myocarditis
cardiovascular complications
arrhythmias
url https://www.vair-journal.com/jour/article/view/446
work_keys_str_mv AT iakozlov cardiovascularcomplicationsofcovid19
AT intyurin cardiovascularcomplicationsofcovid19